Neuropathology of α‐synuclein in Parkinson's disease

Parkinson's disease (PD) is a neurodegenerative disorder characterized by progressive movement disability accompanied by non‐motor symptoms. The neuropathology hallmark of PD is the loss of dopaminergic neurons predominantly in the substantia nigra pars compacta and the presence of intracellular inclusions termed Lewy bodies (LBs), which are mainly composed of α‐synuclein (αSyn). Detailed staging based on the distribution and progression pattern of αSyn pathology in the postmortem brains of PD patients revealed correlation with the clinical phenotypes but not invariably. Cumulative evidence from cell and animal studies has implied that αSyn propagation contributes to the anatomical spread of αSyn pathology in the brain. Here, we recount the studies over the past two centuries on the anatomopathological foundations of PD documented. We also review studies on the structural analysis of αSyn and LBs, Braak staging of αSyn pathology, the cell‐to‐cell propagation of αSyn as well as αSyn fibril polymorphisms, which underlie the phenotypic differences in synucleinopathies.

[1]  Dan Li,et al.  The hereditary mutation G51D unlocks a distinct fibril strain transmissible to wild-type α-synuclein , 2021, Nature Communications.

[2]  C. Dobson,et al.  The release of toxic oligomers from α-synuclein fibrils induces dysfunction in neuronal cells , 2021, Nature Communications.

[3]  S. Murayama,et al.  Lewy pathology of the esophagus correlates with the progression of Lewy body disease: a Japanese cohort study of autopsy cases , 2020, Acta Neuropathologica.

[4]  V. Baekelandt,et al.  The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies , 2020, Acta Neuropathologica.

[5]  G. Knott,et al.  The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration , 2020, Proceedings of the National Academy of Sciences.

[6]  A. Murzin,et al.  Structures of α-synuclein filaments from multiple system atrophy , 2020, Nature.

[7]  K. Nilsson,et al.  Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy , 2020, Nature.

[8]  M. Hasegawa,et al.  Structurally Distinct α‐Synuclein Fibrils Induce Robust Parkinsonian Pathology , 2020, Movement disorders : official journal of the Movement Disorder Society.

[9]  Raphaella W. L. So,et al.  α-Synuclein Strains Target Distinct Brain Regions and Cell Types , 2019, Nature Neuroscience.

[10]  J. Trojanowski,et al.  Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. , 2019, Brain : a journal of neurology.

[11]  P. Alam,et al.  α‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities , 2019, Journal of neurochemistry.

[12]  Nikhil Panicker,et al.  Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease , 2019, Neuron.

[13]  W. V. van IJcken,et al.  Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes , 2019, Nature Neuroscience.

[14]  S. Prusiner,et al.  Multiple system atrophy prions retain strain specificity after serial propagation in two different Tg(SNCA*A53T) mouse lines , 2019, Acta Neuropathologica.

[15]  D. Eisenberg,et al.  Cryo-EM of full-length α-synuclein reveals fibril polymorphs with a common structural kernel , 2018, Alzheimer's & Dementia.

[16]  Gokulakrishna Banumurthy,et al.  α-Synuclein fibril-induced paradoxical structural and functional defects in hippocampal neurons , 2018, Acta neuropathologica communications.

[17]  John L. Robinson,et al.  Cellular Milieu Imparts Distinct Pathological α-Synuclein Strains in α-Synucleinopathies , 2018, Nature.

[18]  J. Kordower,et al.  α-Synuclein nonhuman primate models of Parkinson’s disease , 2018, Journal of Neural Transmission.

[19]  J. Trojanowski,et al.  Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term , 2017, Acta Neuropathologica.

[20]  M. Hasegawa,et al.  Propagation of pathological α-synuclein in marmoset brain , 2017, Acta neuropathologica communications.

[21]  N. Yagi,et al.  Synchrotron FTIR micro-spectroscopy for structural analysis of Lewy bodies in the brain of Parkinson’s disease patients , 2015, Scientific Reports.

[22]  Elliott W. Dirr,et al.  Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration , 2015, Neurobiology of Disease.

[23]  D. Geschwind,et al.  Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism , 2015, Proceedings of the National Academy of Sciences.

[24]  Vivek K Unni,et al.  Progressive aggregation of alpha-synuclein and selective degeneration of Lewy inclusion-bearing neurons in a mouse model of parkinsonism , 2015, Cell reports.

[25]  T. Südhof,et al.  α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation , 2014, Proceedings of the National Academy of Sciences.

[26]  F. Gage,et al.  Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. , 2014, Brain : a journal of neurology.

[27]  E. Bézard,et al.  Lewy body extracts from Parkinson disease brains trigger α‐synuclein pathology and neurodegeneration in mice and monkeys , 2014, Annals of neurology.

[28]  Alexander K. Buell,et al.  The role of stable α-synuclein oligomers in the molecular events underlying amyloid formation. , 2014, Journal of the American Chemical Society.

[29]  B. Meier,et al.  Structural and functional characterization of two alpha-synuclein strains , 2013, Nature Communications.

[30]  Masato Hasegawa,et al.  Prion-like spreading of pathological α-synuclein in brain , 2013, Brain : a journal of neurology.

[31]  J. Trojanowski,et al.  Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice , 2012, Science.

[32]  R. Melki,et al.  Fibrillar α-synuclein and huntingtin exon 1 assemblies are toxic to the cells. , 2012, Biophysical journal.

[33]  Christopher M. Dobson,et al.  Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein , 2012, Cell.

[34]  J. Trojanowski,et al.  Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice , 2012, The Journal of experimental medicine.

[35]  E. Goormaghtigh,et al.  Toxic prefibrillar α-synuclein amyloid oligomers adopt a distinctive antiparallel β-sheet structure. , 2012, The Biochemical journal.

[36]  Tapan P. Patel,et al.  Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death , 2011, Neuron.

[37]  Fred H. Gage,et al.  In vivo demonstration that α-synuclein oligomers are toxic , 2011, Proceedings of the National Academy of Sciences.

[38]  D. Hong,et al.  The role of the C‐terminus of human α‐synuclein: Intra‐disulfide bonds between the C‐terminus and other regions stabilize non‐fibrillar monomeric isomers , 2011, FEBS letters.

[39]  T. Iwatsubo,et al.  Seeded Aggregation and Toxicity of α-Synuclein and Tau , 2010, The Journal of Biological Chemistry.

[40]  A. Björklund,et al.  Characterization of Lewy body pathology in 12‐ and 16‐year‐old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[41]  E. Masliah,et al.  Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits α-Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions , 2010, The Journal of Neuroscience.

[42]  Fabrizio Chiti,et al.  A causative link between the structure of aberrant protein oligomers and their toxicity. , 2010, Nature chemical biology.

[43]  J. Trojanowski,et al.  Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells , 2009, Proceedings of the National Academy of Sciences.

[44]  B. Hyman,et al.  Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. , 2009, The Journal of clinical investigation.

[45]  Michael Wolff,et al.  Seeding induced by α‐synuclein oligomers provides evidence for spreading of α‐synuclein pathology , 2009, Journal of neurochemistry.

[46]  Brian Spencer,et al.  Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.

[47]  R. Hauser,et al.  Transplanted dopaminergic neurons develop PD pathologic changes: A second case report , 2008, Movement disorders : official journal of the Movement Disorder Society.

[48]  Robert E Burke,et al.  A critical evaluation of the Braak staging scheme for Parkinson's disease , 2008, Annals of neurology.

[49]  O. Lindvall,et al.  Research in motion: the enigma of Parkinson's disease pathology spread , 2008, Nature Reviews Neuroscience.

[50]  R. Hauser,et al.  Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.

[51]  Elisabet Englund,et al.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.

[52]  Jun Hu,et al.  Acceleration of α‐synuclein aggregation by homologous peptides , 2006 .

[53]  C. Shults.  Lewy bodies. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[54]  P. Jensen,et al.  Pathogenic effects of α-synuclein aggregation , 2005 .

[55]  Olga Pletnikova,et al.  Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[56]  I. Alafuzoff,et al.  α‐Synuclein pathology does not predict extrapyramidal symptoms or dementia , 2005, Annals of neurology.

[57]  E. Kuusisto,et al.  Morphogenesis of Lewy Bodies: Dissimilar Incorporation of α‐Synuclein, Ubiquitin, and p62 , 2003, Journal of neuropathology and experimental neurology.

[58]  K. Jellinger,et al.  α-Synuclein pathology in Parkinson’s and Alzheimer’s disease brain: incidence and topographic distribution—a pilot study , 2003, Acta Neuropathologica.

[59]  H. Braak,et al.  Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen , 2003, Journal of Neural Transmission.

[60]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[61]  P. Lansbury,et al.  Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. , 2002, Journal of molecular biology.

[62]  B. Hyman,et al.  Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. , 2002, The American journal of pathology.

[63]  M. Perutz,et al.  Aggregation of proteins with expanded glutamine and alanine repeats of the glutamine-rich and asparagine-rich domains of Sup35 and of the amyloid β-peptide of amyloid plaques , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[64]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[65]  Rebecca A. Betensky,et al.  α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[66]  D. Eliezer,et al.  Conformational properties of alpha-synuclein in its free and lipid-associated states. , 2001, Journal of molecular biology.

[67]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[68]  R. Perrin,et al.  Interaction of Human α-Synuclein and Parkinson's Disease Variants with Phospholipids , 2000, The Journal of Biological Chemistry.

[69]  Susan E Daniel,et al.  Characterisation of isolated α-synuclein filaments from substantia nigra of Parkinson's disease brain , 2000, Neuroscience Letters.

[70]  B. Giasson,et al.  Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. , 2000, The Journal of biological chemistry.

[71]  G. Irvine,et al.  Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins. , 2000, Journal of structural biology.

[72]  L. Serpell,et al.  Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[73]  M. Citron,et al.  α-Synuclein Fibrillogenesis Is Nucleation-dependent , 1999, The Journal of Biological Chemistry.

[74]  R. Anthony Crowther,et al.  Synthetic filaments assembled from C‐terminally truncated α‐synuclein , 1998 .

[75]  J Q Trojanowski,et al.  Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein , 1998, Annals of neurology.

[76]  Nigel J. Cairns,et al.  Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.

[77]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[78]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[79]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[80]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[81]  P. Lansbury,et al.  NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.

[82]  David F. Clayton,et al.  Characterization of a novel protein regulated during the critical period for song learning in the zebra finch , 1995, Neuron.

[83]  Akihiko Iwai,et al.  The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.

[84]  E. Masliah,et al.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[85]  K. Watabe,et al.  Immunohistochemistry of neuronal inclusions in the cerebral cortex and brain‐stem in Lewy body disease , 1993, Acta pathologica japonica.

[86]  P. Mulvihill,et al.  Filaments of Lewy bodies contain insoluble cytoskeletal elements. , 1992, The American journal of pathology.

[87]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[88]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[89]  M. Hoehn,et al.  Parkinsonism , 2020, Definitions.

[90]  M. Goldstein,et al.  The effects of ventromedial tegmental lesions on the biosynthesis of catecholamines in the striatum , 1966 .

[91]  T. Sourkes,et al.  INFLUENCE OF THE SUBSTANTIA NIGRA ON THE CATECHOLAMINE CONTENT OF THE STRIATUM. , 1965, Brain : a journal of neurology.

[92]  K. Fuxe,et al.  DEMONSTRATION AND MAPPING OUT OF NIGRO-NEOSTRIATAL DOPAMINE NEURONS. , 1964, Life sciences.

[93]  O. Hornykiewicz,et al.  Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. , 1960, Parkinsonism & related disorders.

[94]  A. Carlsson,et al.  The occurrence, distribution and physiological role of catecholamines in the nervous system. , 1959, Pharmacological reviews.

[95]  A. Carlsson,et al.  3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists , 1957, Nature.

[96]  J. Greenfield,et al.  THE BRAIN-STEM LESIONS IN PARKINSONISM , 1953, Journal of neurology, neurosurgery, and psychiatry.

[97]  W. J. German.  The Diseases of the Basal Ganglia , 1943, The Yale Journal of Biology and Medicine.

[98]  R. Moriyasu.  Zur pathologischen Anatomie der Paralysis agitans , 1908, Archiv für Psychiatrie und Nervenkrankheiten.

[99]  Jhl.  Le??ons sur les Maladies Nerveuses , 1895 .

[100]  P. James.  An Essay on the Shaking Palsy , 1817, The Medico-Chirurgical Journal and Review.

[101]  S. Orimo.  [Autonomic Dysfunction and Skin Biopsy in Dementia with Lewy Bodies]. , 2018, Brain and nerve = Shinkei kenkyu no shinpo.

[102]  He-Jin Lee,et al.  Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. , 2008, The international journal of biochemistry & cell biology.

[103]  P. Leigh,et al.  Relationships between Lewy bodies and pale bodies in Parkinson's disease , 2004, Acta Neuropathologica.

[104]  Hitoshi Takahashi,et al.  Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses , 2004, Acta Neuropathologica.

[105]  Hitoshi Takahashi,et al.  Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system , 2004, Acta Neuropathologica.

[106]  H. Sano.  Biochemistry of the extrapyramidal system Shinkei Kennkyu No Shinpo, Advances in Neurological Sciences. (ISSN 0001-8724) Tokyo, October 1960;5:42-48. , 2000, Parkinsonism & related disorders.

[107]  K. Fuxe,et al.  FURTHER EVIDENCE FOR THE PRESENCE OF NIGRO-NEOSTRIATAL DOPAMINE NEURONS IN THE RAT. , 1965, The American journal of anatomy.

[108]  P. Blocq,et al.  Sur un cas de tremblement parkinsonien hémiplégique symptomatique d'une tumeur du pédoncule cérébral , 1893 .